

Philip A Chambers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2838808/publications.pdf>

Version: 2024-02-01

18
papers

1,983
citations

623188

14
h-index

887659

17
g-index

18
all docs

18
docs citations

18
times ranked

3566
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 253-262.	0.4	0
2	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 253-262.	0.4	1
3	Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. <i>British Journal of Cancer</i> , 2017, 117, 1286-1294.	2.9	22
4	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. <i>Journal of Pathology</i> , 2016, 238, 562-570.	2.1	185
5	Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and BRCA-Like Status, in Both Blood and Tumour DNA. <i>PLoS ONE</i> , 2016, 11, e0160174.	1.1	14
6	Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast Carcinogenesis. <i>PLoS ONE</i> , 2015, 10, e0139698.	1.1	21
7	Mutation Detection by Clonal Sequencing of PCR Amplicons and Grouped Read Typing is Applicable to Clinical Diagnostics. <i>Human Mutation</i> , 2013, 34, 248-254.	1.1	8
8	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. <i>Lancet Oncology</i> , 2013, 14, 749-759.	5.1	333
9	Clinicopathologic Features of V600E and V600K Melanoma Letter. <i>Clinical Cancer Research</i> , 2012, 18, 6792-6792.	3.2	14
10	Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1261-1270.	0.8	593
11	Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing. <i>Analytical Cellular Pathology</i> , 2011, 34, 61-66.	0.7	70
12	In vitro functional effects of XPC gene rare variants from bladder cancer patients. <i>Carcinogenesis</i> , 2011, 32, 516-521.	1.3	10
13	Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. <i>Analytical Cellular Pathology</i> , 2011, 34, 61-6.	0.7	42
14	Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC). <i>Genes Chromosomes and Cancer</i> , 2009, 48, 694-710.	1.5	20
15	Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. <i>Journal of Pathology</i> , 2009, 218, 122-130.	2.1	32
16	KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 5931-5937.	0.8	517
17	Ischemia-reperfusion Injury and Its Influence on the Epigenetic Modification of the Donor Kidney Genome. <i>Transplantation</i> , 2008, 86, 1818-1823.	0.5	45
18	Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2005, 11, 5740-5747.	3.2	56